跳到正文
原文
Endpoints News 生物医药· Ayisha Sharma·· 2026-10-06AI 评分50

AbbVie 与 Genmab 称 Epkinly 在一线 DLBCL 后期临床试验中取得成功

AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy

AI 导读

AbbVie 与 Genmab 表示,其 T 细胞衔接器 Epkinly 在一线弥漫性大 B 细胞淋巴瘤后期临床试验中取得成功,为潜在市场准入铺路。报道将该结果定位为对 Polivy 的挑战,原文未披露具体疗效数据。

正文

Ab­b­Vie and Gen­mab said their T-cell en­gager Ep­kin­ly passed a late-stage tri­al in first-line dif­fuse large B-cell lym­phoma, clear­ing the way for a po­ten­tial mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news